Brain Region-Dependent Alternative Splicing of Alzheimer Disease (AD)-Risk Genes Is Associated With Neuropathological Features in AD
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Alzheimer disease (AD) is one of the most complex diseases and is characterized by AD-related neuropathological features, including accumulation of amyloid-β plaques and tau neurofibrillary tangles. Dysregulation of alternative splicing (AS) contributes to these features, and there is heterogeneity in features across brain regions between AD patients, leading to different severity and progression rates; however, brain region-specific AS mechanisms still remain unclear. Therefore, we aimed to systemically investigate AS in multiple brain regions of AD patients and how they affect clinical features. Methods: We analyzed RNA sequencing (RNA-Seq) data obtained from brain regions (frontal and temporal) of AD patients. Reads were mapped to the hg19 reference genome using the STAR aligner, and exon skipping (ES) rates were estimated as percent spliced in (PSI) by rMATs. We focused on AD-risk genes discovered by genome-wide association studies, and accordingly evaluated associations between PSI of skipped exons in AD-risk genes and Braak stage and plaque density mean (PM) for each brain region. We also integrated whole-genome sequencing data of the ascertained samples with RNA-Seq data to identify genetic regulators of feature-associated ES. Results: We identified 26 and 41 ES associated with Braak stage in frontal and temporal regions, respectively, and 10 and 50 ES associated with PM. Among those, 10 were frontal-specific (CLU and NTRK2), 65 temporal-specific (HIF1A and TRPC4AP), and 26 shared ES (APP) that accompanied functional Gene Ontology terms, including axonogenesis in shared-ES genes. We further identified genetic regulators that account for 44 ES (44% of the total). Finally, we present as a case study the systematic regulation of an ES in APP, which is important in AD pathogenesis. Conclusions: This study provides new insights into brain region-dependent AS regulation of the architecture of AD-risk genes that contributes to AD pathologies, ultimately allowing identification of a treatment target and region-specific biomarkers for AD.
Abstract
Purpose: Alzheimer disease (AD) is one of the most complex diseases and is characterized by AD-related neuropathological features, including accumulation of amyloid-β plaques and tau neurofibrillary tangles. Dysregulation of alternative splicing (AS) contributes to these features, and there is heterogeneity in features across brain regions between AD patients, leading to different severity and progression rates; however, brain region-specific AS mechanisms still remain unclear. Therefore, we aimed to systemically investigate AS in multiple brain regions of AD patients and how they affect clinical features. Methods: We analyzed RNA sequencing (RNA-Seq) data obtained from brain regions (frontal and temporal) of AD patients. Reads were mapped to the hg19 reference genome using the STAR aligner, and exon skipping (ES) rates were estimated as percent spliced in (PSI) by rMATs. We focused on AD-risk genes discovered by genome-wide association studies, and accordingly evaluated associations between PSI of skipped exons in AD-risk genes and Braak stage and plaque density mean (PM) for each brain region. We also integrated whole-genome sequencing data of the ascertained samples with RNA-Seq data to identify genetic regulators of feature-associated ES. Results: We identified 26 and 41 ES associated with Braak stage in frontal and temporal regions, respectively, and 10 and 50 ES associated with PM. Among those, 10 were frontal-specific (CLU and NTRK2), 65 temporal-specific (HIF1A and TRPC4AP), and 26 shared ES (APP) that accompanied functional Gene Ontology terms, including axonogenesis in shared-ES genes. We further identified genetic regulators that account for 44 ES (44% of the total). Finally, we present as a case study the systematic regulation of an ES in APP, which is important in AD pathogenesis. Conclusions: This study provides new insights into brain region-dependent AS regulation of the architecture of AD-risk genes that contributes to AD pathologies, ultimately allowing identification of a treatment target and region-specific biomarkers for AD.
참고문헌 (40)
- Cummings JL, "Alzheimer disease", JAMA, 287, pp.2335~2338 (2002)
- Serrano-Pozo A, "Neuropathological alterations in Alzheimer disease", Cold Spring Harb Perspect Med, 1, pp.a006189~ (2011)
- Wightman DP, "A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease", Nat Genet, 53, pp.1276~1282 (2021)
- Tan L, "Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts", Sci Rep, 6, pp.26027~ (2016)
- Han S, "Alternative splicing regulation of an Alzheimer’s risk variant in CLU", Int J Mol Sci, 21, pp.7079~ (2020)
- Sutherland GT, "Understanding the pathogenesis of Alzheimer’s disease : will RNA-Seq realize the promise of transcriptomics", J Neurochem, 116, pp.937~946 (2011)
- Han S, "ADASviewer : web-based application for integrative analysis of multiomics data in Alzheimer’s disease", NPJ Syst Biol Appl, 7, pp.18~ (2021)
- Han S, "Identification of exon skipping events associated with Alzheimer’s disease in the human hippocampus", BMC Med Genomics, 12(Suppl 1), pp.13~ (2019)
- Wang ET, "Alternative isoform regulation in human tissue transcriptomes", Nature, 456, pp.470~476 (2008)
- Mills JD, "RNA-Seq analysis of the parietal cortex in Alzheimer’s disease reveals alternatively spliced isoforms related to lipid metabolism", Neurosci Lett, 536, pp.90~95 (2013)
- De Jonghe C, "Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer’s disease by increased Abeta42secretion", Hum Mol Genet, 8, pp.1529~1540 (1999)
- Han S, "Alternative splicing regulation of low-frequency genetic variants in exon 2 of TREM2 in Alzheimer’s disease by splicing-based aggregation", Int J Mol Sci, 22, pp.9865~ (2021)
- Lin L, "Regionspecific expression of tau, amyloid-beta protein precursor, and synaptic proteins at physiological condition or under endoplasmic reticulum stress in rats", J Alzheimers Dis, 41, pp.1149~1163 (2014)
- DeTure MA, "The neuropathological diagnosis of Alzheimer’s disease", Mol Neurodegener, 14, pp.32~ (2019)
- Braak H, "Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry", Acta Neuropathol, 112, pp.389~404 (2006)
- Zhang Y, "Regional variation of splicing QTLs in human brain", Am J Hum Genet, 107, pp.196~210 (2020)
- He L, "Allele-specific analysis reveals exonand cell-type-specific regulatory effects of Alzheimer’s disease-associated genetic variants", Transl Psychiatry, 12, pp.163~ (2022)
- Wang M, "The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer’s disease", Sci Data, 5, pp.180185~ (2018)
- Li H, "The sequence alignment", map format and SAMtools, 2009, pp.25, 2078~2079
- Dobin A, "STAR : ultrafast universal RNA-seq aligner", Bioinformatics, 29, pp.15~21 (2013)
- Shen L, "An overview of genome-wide association studies in Alzheimer’s disease", Neurosci Bull, 32, pp.183~190 (2016)
- Shen S, "rMATS : robust and flexible detection of differential alternative splicing from replicate RNA-Seq data", Proc Natl Acad Sci U S A, 111, pp.E5593~E5601 (2014)
- Eden E, "GOrilla : a tool for discovery and visualization of enriched GO terms in ranked gene lists", BMC Bioinformatics, 10, pp.48~ (2009)
- Szklarczyk D, "STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets", Nucleic Acids Res, 47(D1), pp.D607~D613 (2019)
- Shannon P, "Cytoscape : a software environment for integrated models of biomolecular interaction networks", Genome Res, 13, pp.2498~2504 (2003)
- Zhang M, "Axonogenesis is coordinated by neuron-specific alternative splicing programming and splicing regulator PTBP2", Neuron, 101, pp.690~706.e10 (2019)
- Fabregat A, "The Reactome Pathway Knowledgebase", Nucleic Acids Res, 46(D1), pp.D649~D655 (2017)
- Kanehisa M, "KEGG : kyoto encyclopedia of genes and genomes", Nucleic Acids Res, 28, pp.27~30 (2000)
- Kamburov A, "ConsensusPath-DB--a database for integrating human functional interaction networks", Nucleic Acids Res, 37(Database issue), pp.D623~D628 (2009)
- Wan T, "Research progress on mechanism of neuroprotective roles of Apelin-13 in prevention and treatment of Alzheimer’s disease", Neurochem Res, 47, pp.205~217 (2022)
- Yamaguchi K, "Splicing QTL analysis focusing on coding sequences reveals mechanisms for disease susceptibility loci", Nat Commun, 13, pp.4659~ (2022)
- Tam V, "Benefits and limitations of genome-wide association studies", Nat Rev Genet, 20, pp.467~484 (2019)
- Zhang YW, "APP processing in Alzheimer’s disease", Mol Brain, 4, pp.3~ (2011)
- Cuchillo-Ibanez I, "The apolipoprotein receptor LRP3 compromises APP levels", Alzheimers Res Ther, 13, pp.181~ (2021)
- Passarella D, "Low-density lipoprotein receptor-related protein 8 at the crossroad between cancer and neurodegeneration", Int J Mol Sci, 23, pp.8921~ (2022)
- Hinrich AJ, "Therapeutic correction of ApoER2 splicing in Alzheimer’s disease mice using antisense oligonucleotides", EMBO Mol Med, 8, pp.328~345 (2016)
- Van C, "Targeted deletion of PAC1 receptors in retinal neurons enhances neuron loss and axonopathy in a model of multiple sclerosis and optic neuritis", Neurobiol Dis, 160, pp.105524~ (2021)
- Salameh MA, "The amyloid precursor protein", protease nexin 2Kunitz inhibitor domain is a highly specific substrate of mesotrypsin, 2010, pp.285, 1939~1949
- Hooli BV, "Role of common and rare APP DNA sequence variants in Alzheimer disease", Neurology, 78, pp.1250~1257 (2012)
- Salehi A, "Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration", Neuron, 51, pp.29~42 (2006)